Cargando…
Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may affect testicles. Lower testosterone levels have been associated with worse clinical outcomes and higher mortality. Our objective was to evaluate the hypothalamic–pituitary–gonadal axis of men admitted with SARS-CoV-2 p...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025790/ https://www.ncbi.nlm.nih.gov/pubmed/35453570 http://dx.doi.org/10.3390/biomedicines10040820 |
_version_ | 1784690961261002752 |
---|---|
author | Marinelli, Lorenzo Beccuti, Guglielmo Zavattaro, Marco Cagnina, Serena Gesmundo, Iacopo Bona, Chiara Lopez, Chiara Scabini, Silvia Canta, Francesca Mornese Pinna, Simone Lupia, Tommaso Di Bisceglie, Cataldo Ponzetto, Federico Settanni, Fabio De Rosa, Francesco Giuseppe Ghigo, Ezio Motta, Giovanna |
author_facet | Marinelli, Lorenzo Beccuti, Guglielmo Zavattaro, Marco Cagnina, Serena Gesmundo, Iacopo Bona, Chiara Lopez, Chiara Scabini, Silvia Canta, Francesca Mornese Pinna, Simone Lupia, Tommaso Di Bisceglie, Cataldo Ponzetto, Federico Settanni, Fabio De Rosa, Francesco Giuseppe Ghigo, Ezio Motta, Giovanna |
author_sort | Marinelli, Lorenzo |
collection | PubMed |
description | Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may affect testicles. Lower testosterone levels have been associated with worse clinical outcomes and higher mortality. Our objective was to evaluate the hypothalamic–pituitary–gonadal axis of men admitted with SARS-CoV-2 pneumonia and its link with the pneumonia-treatment intensification. Short-term changes in hormonal parameters were also assessed. Methods: Men admitted with SARS-CoV-2 pneumonia were recruited in two different hospitals in Piedmont, Italy. In all patients, the assessment of total testosterone (TT), calculated free testosterone (cFT), gonadotropins, inhibin B (InhB), and other biochemical evaluations were performed at admission (T0) and before discharge (T1). Through a review of medical records, clinical history was recorded, including data on pneumonia severity. Results: Thirty-five men (median age 64 [58–74] years) were recruited. Lower TT and cFT levels at T0 were associated with CPAP therapy (p = 0.045 and 0.028, respectively), even after adjusting for age and PaO(2)/FIO(2) ratio in a multivariable analysis. In those discharged alive, lower TT and cFT levels were associated with longer hospital stay (p < 0.01). TT, cFT, and InhB were below the normal range at T0 and significantly increased at T1 (TT 1.98 [1.30–2.72] vs. 2.53 [1.28–3.37] ng/mL, p = 0.038; cFT (0.0441 [0.0256–0.0742] vs. 0.0702 [0.0314–0.0778] ng/mL, p = 0.046; InhB 60.75 [25.35–88.02] vs. 77.05 [51.15–134.50], p < 0.01). Conclusions: Both TT and cFT levels are associated with adverse clinical outcomes in men admitted with SARS-CoV-2 pneumonia. As TT, cFT and InhB levels increase before discharge, short-term functional recovery of steroidogenesis and an indirect improvement of spermatozoa functional status could be hypothesized. |
format | Online Article Text |
id | pubmed-9025790 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90257902022-04-23 Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia Marinelli, Lorenzo Beccuti, Guglielmo Zavattaro, Marco Cagnina, Serena Gesmundo, Iacopo Bona, Chiara Lopez, Chiara Scabini, Silvia Canta, Francesca Mornese Pinna, Simone Lupia, Tommaso Di Bisceglie, Cataldo Ponzetto, Federico Settanni, Fabio De Rosa, Francesco Giuseppe Ghigo, Ezio Motta, Giovanna Biomedicines Article Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may affect testicles. Lower testosterone levels have been associated with worse clinical outcomes and higher mortality. Our objective was to evaluate the hypothalamic–pituitary–gonadal axis of men admitted with SARS-CoV-2 pneumonia and its link with the pneumonia-treatment intensification. Short-term changes in hormonal parameters were also assessed. Methods: Men admitted with SARS-CoV-2 pneumonia were recruited in two different hospitals in Piedmont, Italy. In all patients, the assessment of total testosterone (TT), calculated free testosterone (cFT), gonadotropins, inhibin B (InhB), and other biochemical evaluations were performed at admission (T0) and before discharge (T1). Through a review of medical records, clinical history was recorded, including data on pneumonia severity. Results: Thirty-five men (median age 64 [58–74] years) were recruited. Lower TT and cFT levels at T0 were associated with CPAP therapy (p = 0.045 and 0.028, respectively), even after adjusting for age and PaO(2)/FIO(2) ratio in a multivariable analysis. In those discharged alive, lower TT and cFT levels were associated with longer hospital stay (p < 0.01). TT, cFT, and InhB were below the normal range at T0 and significantly increased at T1 (TT 1.98 [1.30–2.72] vs. 2.53 [1.28–3.37] ng/mL, p = 0.038; cFT (0.0441 [0.0256–0.0742] vs. 0.0702 [0.0314–0.0778] ng/mL, p = 0.046; InhB 60.75 [25.35–88.02] vs. 77.05 [51.15–134.50], p < 0.01). Conclusions: Both TT and cFT levels are associated with adverse clinical outcomes in men admitted with SARS-CoV-2 pneumonia. As TT, cFT and InhB levels increase before discharge, short-term functional recovery of steroidogenesis and an indirect improvement of spermatozoa functional status could be hypothesized. MDPI 2022-03-31 /pmc/articles/PMC9025790/ /pubmed/35453570 http://dx.doi.org/10.3390/biomedicines10040820 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Marinelli, Lorenzo Beccuti, Guglielmo Zavattaro, Marco Cagnina, Serena Gesmundo, Iacopo Bona, Chiara Lopez, Chiara Scabini, Silvia Canta, Francesca Mornese Pinna, Simone Lupia, Tommaso Di Bisceglie, Cataldo Ponzetto, Federico Settanni, Fabio De Rosa, Francesco Giuseppe Ghigo, Ezio Motta, Giovanna Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia |
title | Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia |
title_full | Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia |
title_fullStr | Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia |
title_full_unstemmed | Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia |
title_short | Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia |
title_sort | testosterone as a biomarker of adverse clinical outcomes in sars-cov-2 pneumonia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025790/ https://www.ncbi.nlm.nih.gov/pubmed/35453570 http://dx.doi.org/10.3390/biomedicines10040820 |
work_keys_str_mv | AT marinellilorenzo testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia AT beccutiguglielmo testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia AT zavattaromarco testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia AT cagninaserena testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia AT gesmundoiacopo testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia AT bonachiara testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia AT lopezchiara testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia AT scabinisilvia testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia AT cantafrancesca testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia AT mornesepinnasimone testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia AT lupiatommaso testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia AT dibiscegliecataldo testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia AT ponzettofederico testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia AT settannifabio testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia AT derosafrancescogiuseppe testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia AT ghigoezio testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia AT mottagiovanna testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia |